Pavet V - Search Results

1

Thioether analogues of disulfide-bridged cyclic peptides targeting death receptor 5: conformational analysis, dimerisation and consequences for receptor activation.

Pulka-Ziach K, Pavet V, Chekkat N, Estieu-Gionnet K, Rohac R, Lechner MC, Smulski CR, Zeder-Lutz G, Altschuh D, Gronemeyer H, Fournel S, Odaert B, Guichard G. Pulka-Ziach K, et al. Among authors: pavet v. Chembiochem. 2015 Jan 19;16(2):293-301. doi: 10.1002/cbic.201402485. Epub 2014 Dec 8. Chembiochem. 2015. PMID: 25487639

2

Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity.

Pavet V, Beyrath J, Pardin C, Morizot A, Lechner MC, Briand JP, Wendland M, Maison W, Fournel S, Micheau O, Guichard G, Gronemeyer H. Pavet V, et al. Cancer Res. 2010 Feb 1;70(3):1101-10. doi: 10.1158/0008-5472.CAN-09-2889. Epub 2010 Jan 26. Cancer Res. 2010. PMID: 20103630 Free article.

3

Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells.

Shlyakhtina Y, Pavet V, Gronemeyer H. Shlyakhtina Y, et al. Among authors: pavet v. Cell Death Dis. 2017 Aug 31;8(8):e3025. doi: 10.1038/cddis.2017.423. Cell Death Dis. 2017. PMID: 29048428 Free PMC article.

4

Towards novel paradigms for cancer therapy.

Pavet V, Portal MM, Moulin JC, Herbrecht R, Gronemeyer H. Pavet V, et al. Oncogene. 2011 Jan 6;30(1):1-20. doi: 10.1038/onc.2010.460. Epub 2010 Oct 11. Oncogene. 2011. PMID: 20935674 Review.

5

Plasminogen activator urokinase expression reveals TRAIL responsiveness and supports fractional survival of cancer cells.

Pavet V, Shlyakhtina Y, He T, Ceschin DG, Kohonen P, Perälä M, Kallioniemi O, Gronemeyer H. Pavet V, et al. Cell Death Dis. 2014 Jan 30;5(1):e1043. doi: 10.1038/cddis.2014.5. Cell Death Dis. 2014. PMID: 24481457 Free PMC article.

6

Human cells contain natural double-stranded RNAs with potential regulatory functions.

Portal MM, Pavet V, Erb C, Gronemeyer H. Portal MM, et al. Among authors: pavet v. Nat Struct Mol Biol. 2015 Jan;22(1):89-97. doi: 10.1038/nsmb.2934. Epub 2014 Dec 15. Nat Struct Mol Biol. 2015. PMID: 25504323

7

TARDIS, a targeted RNA directional sequencing method for rare RNA discovery.

Portal MM, Pavet V, Erb C, Gronemeyer H. Portal MM, et al. Among authors: pavet v. Nat Protoc. 2015 Dec;10(12):1915-38. doi: 10.1038/nprot.2015.120. Epub 2015 Oct 29. Nat Protoc. 2015. PMID: 26513670

8

MiR-378a inhibits glucose metabolism by suppressing GLUT1 in prostate cancer.

Cannistraci A, Hascoet P, Ali A, Mundra P, Clarke NW, Pavet V, Marais R. Cannistraci A, et al. Among authors: pavet v. Oncogene. 2022 Mar;41(10):1445-1455. doi: 10.1038/s41388-022-02178-0. Epub 2022 Jan 17. Oncogene. 2022. PMID: 35039635 Free PMC article.

9

Direct in vivo cellular reprogramming involves transition through discrete, non-pluripotent steps.

Richard JP, Zuryn S, Fischer N, Pavet V, Vaucamps N, Jarriault S. Richard JP, et al. Among authors: pavet v. Development. 2011 Apr;138(8):1483-92. doi: 10.1242/dev.063115. Epub 2011 Mar 9. Development. 2011. PMID: 21389048 Free PMC article.

10

Map3k1 Loss Cooperates with Braf^V600E to Drive Melanomagenesis.

Trucco LD, Mundra PA, García-Martínez P, Hogan K, Baenke F, Dhomen N, Pavet V, Marais R. Trucco LD, et al. Among authors: pavet v. J Invest Dermatol. 2021 Jan;141(1):221-225.e6. doi: 10.1016/j.jid.2020.05.085. Epub 2020 May 22. J Invest Dermatol. 2021. PMID: 32450073 Free article. Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15 results

Search Page

Filters